Table 4 Distribution of breast cancer phenotype on residual disease according to HER2 expression.

From: HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment

 

HER2–0, n (%)

HER2-low-positive, n (%)

p-value

RD phenotype

  

<0.001a

HR+/HER2–

36 (34.6)

68 (65.4)

TN

58 (62.4)

35 (37.6)

  1. RD residual disease, HR+ hormone-receptor positive, HER2– HER2-negative, TN triple-negative.
  2. aχ2 test.
Back to article page